CADTH | Evidence Driven
CADTH | Evidence Driven

Once-weekly Isoniazid and Rifapentine for 12 Weeks for the Treatment of Latent Tuberculosis Infection: Clinical Utility and Cost-Effectiveness

Details

Files
Project Status:
Completed
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA1129-000

Question

  1.  What is the clinical utility of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection?
  2.  What is the cost-effectiveness of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection?

     

Key Message

Two systematic reviews with meta-analyses, one systematic review with a network meta-analysis, five randomized controlled trials and ten non-randomized studies were identified regarding the clinical utility of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection. Additionally, two economic evaluations were identified regarding the cost-effectiveness of once-weekly isoniazid and rifapentine for 12 weeks for the treatment of latent tuberculosis infection.

Files

Once-weekly Isoniazid and Rifapentine for 12 Weeks for the Treatment of Latent Tuberculosis Infection: Clinical Utility and Cost-Effectiveness Rapid Response August 4, 2020 View PDF

Related Content

Last Updated : August 14, 2020